Search for a trial

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection

The primary objective of this Registry is:• To evaluate HCV viral sequences and the persistence or evolution of treatment emergent viral mutations in subjects who fail to achieve an SVR after treatment with a Gilead oral antiviral containing regimen…

Evaluation of the CAP-value for quantitating liver steatosis using 1H-MRS and liver biopsy as reference standard

Main objective: investigate the correlation between CAP-values with fat percentages found at 1H-MR Spectroscopy and steatosis grade at liver biopsy. Secondary objectives: investigate the reproducibility of CAP-measurements; investigate the…

Monitoring the intrahepatic immune responses in chronic HBV patients after long-term treatment with tenofovir

Study of the phenotype and function of NK cells obtained from peripheral blood and liver of patients who are successfully being treated for at least 3-4 years for their chronic HBV infection with tenofovir in a flow-up study (METC nr. 2008-271).

Immunogenetic and therapeutic aspects of Autoimmune Hepatitis

Primary Objective: To gain more insight in the genetic susceptibility for AIH. For this we will study the presence of candidate genes in AIH patients, study genetic similarities with other auto-immune diseases and perform a whole genome association…

A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH)

Primary objective:- To determine the effect of LIK066 on Liver Function test after 12 weeks of treatmentSecondary objectives: - To determine the effect of LIK066 on intrahepatic lipid after 12 weeks of treatment- To determine the effect of LIK066 on…

Immune phenotyping in chronic HCV patients treated with Sofosbuvir and Daclatasvir combination for 12 or 24 weeks * SODA study

Primary objectiveThe primary objective for this study is to analyse the impact of inhibition of viral replication by interferon-free therapy consisting of Sofosbuvir and Daclatasvir (±Ribavirin) on the phenotype and function of the innate immune…

Liver fat accumulation in inflammatory bowel disease

To compare accumulation of liver fat (as measured using CAP) and liver fibrosis (as measured using fibroscan) between patients with quiescent and active inflammatory bowel disease

The long-term follow-up interferon-α treatment for chronic hepatitis B infection

To study the long-term effects of interferon-α treatment for chronic hepatitis B patients infection.

Evaluation of the CAP-value for quantitating liver steatosis in obese children using 1H-MRS as reference standard

To investigate the correlation between the CAP-value measured with the FibroScan® device and liver fat percentage measured with 1H-MRS in a well-characterized cohort of obese children at risk of having fatty liver disease.

Discovery of non-invasive biomarkers for immune-mediated liver diseases; AIH, DILI, NAFL and NASH.

The primary aim of this project is to discover new cellular (non-invasive) biomarkers for the diagnosis and monitoring of immune-mediated liver diseases. Secondly we aim to effectively differentiate AIH from DILI and NAFL from NASH.

Liver Fibrosis in a Home Parenteral Nutrition Cohort

main objective: Investigate the prevalence of liver fibrosis according to TE values in children enrolled in a HPN-program. Secondary objectives: Investigate the correlation between TE values and ELF test score and APRI in children enrolled in a HPN-…

Effect of total parenteral feeding on the postprandial bile acid response

In this study, we aim to investigate the difference in the anabolic postprandial bile acid response between an enteral and parenteral mixed meal test (MMT) in healthy lean men. This study is important because it may give a better understanding of…

Population pharmacokinetics and pharmacodynamics of sorafenib in hepatocellular carcinoma patients with Child Pugh B liver cirrhosis

1. To optimize sorafenib treatment in patients with HCC and CP-B liver cirrhosis by exploration of sorafenib exposure, its variability and predictive factors .Secondary:2. To assess the relation between sorafenib exposure and both toxicity and…

A feasibility study comparing two strategies of oral contrast in patients undergoing contrast-enhanced abdominal CT: 50 ml Télébrix Gastro + 950 ml water vs 1000 ml water only.

The aim of this study is to compare the image quality, diagnostic confidence and patient discomfort when using either positive (50 ml Télébrix Gastro + 950 ml water ) or negative 1000 ml water only in outpatients undergoing a contrast-enhanced…

Grazoprevir (MK-5172) + Elbasvir (MK-8742) for the treatment of ACUTE hepatitis C genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)

The goal of this study is to document the efficacy of a shortened 8-week therapy with grazoprevir and elbasvir in patients with acute HCV genotype 1 or 4 infection.

An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment.

-The primary objective of this study is to investigate the pharmacokinetics (PK) of olaparib after a single oral dose of 300 mg to patients with advanced solid tumours and mild or moderate hepatic impairment compared to those with normal hepatic…

A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency

(Protocol Am2 dd. 20-Feb-2014, p17/93)The primary objectives of this study are:- To evaluate the safety of sofosbuvir (SOF) 200 mg or 400 mg + ribavirin (RBV) for 24 weeks as assessed by review of the accumulated safety data in each treatment arm-…

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib

The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib.

*T1-mapping for functional MR imaging of the liver in Primary Sclerosing Cholangitis

Investigate whether *T1-mapping of the liver with the liver specific MRI contrast agent Gd-EOB-DTPA allows measurement of the change in liver function after ERCP treatment of a dominant stricture in PSC patients.

Effects of DDAVP (1-deamino-8-D arginine vasopressin) infusion on parameters of hemostasis in patients with liver cirrhosis

This study aims to collect biochemical evidence for the pro-hemostatic capacity of DDAVP in patients with cirrhosis, in order to proceed towards a more rational clinical use of this drug.